An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors

Journal of Infectious Diseases

Volumn 190, Issue 12, 2004, Pages 2129-2136

  Okayama, Akiko ^a   Mikasa, Keiichi ^a   Matsui, Norio ^a   Higashi, Nobutaka ^a   Miyamoto, Mamiko ^a   Kita, Eiji ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; PENTOXIFYLLINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SHIGA TOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN INJURY; CALORIE; CELL STRAIN CACO 2; CONTROLLED STUDY; ENTEROBACTER INFECTION; EPITHELIUM CELL; ESCHERICHIA COLI; FEMALE; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MALNUTRITION; SURVIVAL RATE;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BRAIN DISEASES; CECUM; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROTEIN-ENERGY MALNUTRITION; ROLIPRAM; SHIGA-LIKE TOXIN II;

EID: 10444224009     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425982     Document Type: Article

References (41)

1. Pickering LK, Obrig TG, Stapleton FB. Hemolytic uremic syndrome and enterohemorrhagic Escherichia coli. Pediatr Infect Dis J 1994; 13: 459-76.
2. Matussek A, Lauber J, Bergau A, et al. Molecular and functional analysis of Shiga toxin induced response patterns in human vascular endothelial cells. Blood 2003; 102:1323-32.
3. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450-79.
4. Obrig TG. Shiga toxin mode of action in E. coli O157:H7 disease. Front Biosci 1997; 2:635-42.
5. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-46.
6. Eskes C, Juillerat-Jeanneret L, Leuba G, Honegger P, Monnet-Tschudi F. Involvement of microglia-neuron interactions in the tumor necrosis factor-α release, microglial activation, and neurodegeneration induced by trimethyltin. J Neurosci Res 2003; 71:583-90.
7. Zajicek IP, Wing M, Scolding NJ, Compston DA. Interactions between oligodendrocytes and microglia: a major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 1992; 115:1611-31.
8. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108:671-80.
9. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157:351-70.
10. Yoshikawa M, Suzumura A, Tamaru T, Takayanagi T, Sawada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scler 1999; 5:126-33.
11. Ekholm D, Hemmer B, Gao G, et al. Differential expression of cAMP cyclic nucleotide phosphodiesterase PDE3 and PDE4 activities in human T cell clones specific for myelin basic protein. J Immunol 1997; 159:1520-9.
12. Kurioka T, Yunou Y, Kita E. Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice. Infect Immun 1998; 66:1726-34.
13. Griffin PM, Ostroff SM, Tauxe RV, et al. Illnesses associated with Escherichia coli 0157:H7 infections: a broad clinical spectrum. Ann Intern Med 1988; 109:705-12.
14. Nicklasson M, Bjöman S, Roth B, Jönsson M, Höglund P. Stereo-selective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 2002; 14:643-52.
15. Gale DD, Landells LJ, Spina D, et al. Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE) 4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol 2002; 54:478-84.
16. Kita E, Yunou Y, Kurioka T, et al. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 2000; 68:1207-14.
17. Kurioka T, Yunou Y, Harada H, Kita E. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Eur J Clin Microbiol Infect Dis 1999; 18:561-71.
18. Stern BK. Some biochemical properties of suspensions of intestinal epithelial cells. Gastroenterology 1966; 51:855-64.
19. Nishikawa K, Matsuoka K, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci USA 2002; 99:7669-74.
20. Martinez AD, Eugenin EA, Branes MC, Bennett MV, Saez JC Identification of second messengers that induce expression of functional gap junctions in microglia cultured from newborn rats. Brain Res 2002; 943:191-201.
21. Deocharan B, Qing X, Lichauco J, Putterman C. α-Actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002; 168:3072-8.
22. Stridden PK, Hughes AK, Ergonul Z, Kohan DE. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002; 186:976-82.
23. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80:849-57.
24. Yagi H, Narita N, Matsumoto M, et al. Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157. Am J Hematol 2001; 66:105-15.
25. Watanabe M, Matsuoka K, Kita E, et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 2004; 189:360-8.
26. Bigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukocyte Biol 1998; 63:101-7.
27. Severn A, Rapson NT, Hunter CA, Liew FY. Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 1992; 148:3441-5.
28. Verghese MW, Snyderman R. Hormonal activation of adenylate cyclase in macrophage membranes is regulated by guanine nucleotides. J Immunol 1983; 130:869-73.
29. Zinyama RB, Bancroft GJ, Sigola LB. Adrenaline suppression of the macrophage nitric oxide response to lipopolysaccharide is associated with differential regulation of tumour necrosis factor-alpha and interleukin-10. Immunology 2001; 104:439-46.
30. Bergmann M, Gornikiewicz A, Sautner T, et al. Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock 1999; 12:421-7.
31. Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis 1999; 180:1205-13.
32. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996; 97:713-9.
33. Alves-Rosa F, Beigier-Bompadre M, Fernandez G, et al. Tolerance to lipopolysaccharide (LPS) regulates the endotoxin effects on Shiga toxin-2 lethality. Immunol Lett 2001; 76:125-31.
34. Hughes AK, Stridden PK, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 1998; 54:426-37.
35. Ohshima T, Schiffmann R, Murray GJ, et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 1999; 96:6423-7.
36. Lin G, Bornfeldt KE. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem Biophys Res Commun 2002; 290:663-9.
37. Kovbasnjuk O, Edidin M, Donowitz M. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci 2001; 114:4025-31.
38. Folcik VA, Smith T, O'Bryant S, et al. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J Neuroimmunol 1999; 97:119-28.
39. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets: isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol 1986; 35:787-800.
40. Macphee CH, Harrison SA, Beavo IA. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci USA 1986; 83:6660-3.
41. Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, Tanaka I. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 2002; 42:262-9.